Skip to content

Rudi Kundini, Pamoja Kundini

Strengthening the Continuity of HIV Care in Tanzania With Economic Support: Phase II

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05373095
Acronym
RKPK: Phase II
Enrollment
692
Registered
2022-05-13
Start date
2023-10-23
Completion date
2026-04-10
Last updated
2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV (Human Immunodeficiency Virus)

Keywords

Tanzania, Conditional Cash Transfers, People Living With HIV, Machine Learning

Brief summary

This protocol describes an individually randomized trial that will include adult people living with HIV (PLHIV) currently receiving HIV care at one of two participating health facilities and identified as high risk for disengagement from care by a machine learning algorithm. Participants randomized to the control arm will receive standard of care HIV clinical services according to Tanzania's National Guidelines for the management of HIV. For those who meet clinic eligibility criteria for enhanced adherence counseling, which at the included study sites is when client's viral load reaches a detectable level (\>1000 copies/ml), this includes the standard provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions, starting on the day of the result and for two months after. Intervention arm participants will receive the same standard HIV care services plus the offer of a cash transfer paired with visit attendance and attendance at each of the three adapted enhanced adherence counseling sessions (referred to as PKC sessions).

Detailed description

This protocol describes a 2-armed parallel individually randomized controlled trial for which 692 PLHIV who meet eligibility criteria, are currently accessing care at a participating health facility (Katoro Health Center, Geita Town Council Hospital, Geita Regional Referral Hospital, or Nyankumbu Health Center), and have provided informed consent to be part of the study will be randomized in a 1:1 ratio (n=346 PLHIV in each arm), stratified by site, to the control or intervention group. The investigators will use machine learning to finalize a predictive model based on routinely collected medical and pharmacy record data to identify and recruit PLHIV for participation at participating facilities who are at high-risk for disengaging from HIV care. Eligible and consenting participants randomized to the control arm will receive standard of care HIV clinical services according to Tanzania's National Guidelines for the Management of HIV. Criteria for enrollment into enhanced adherence counseling sessions includes when client's viral load reaches a detectable level (\>1000 copies/ml). Enhanced adherence counseling includes the standard provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions, starting on the day of the result and for two months after. Counseling focuses on the meaning of viral loads and supportive, non-judgmental strategies for adherence and visit attendance. Sessions are conducted in an individual, 1:1 setting with a trained counselor who is on the clinical staff, or in a group setting with a trained counselor who is on the clinical staff. A minimum of three sessions are required. Eligible and consenting participants randomized to the intervention arm will receive the same standard HIV care services plus the offer of a cash transfer paired with visit attendance and attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first payment will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining enhanced adherence counseling sessions. Due to the nature of the intervention, participants will not be blinded to intervention assignment. The primary endpoint is viral load suppression (\<1000 copies/ml) at 12 months following study enrollment.

Interventions

BEHAVIORALPKC (adapted adherence counseling) and Conditional Cash Transfers

The intervention includes up to 3 cash transfers of 22,500 Tanzanian Shillings (\~$10) paired with attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first cash transfer will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining PKC sessions. The cash transfers will include extra funds for transaction fees, typically \<$1.

Sponsors

University of California, Berkeley
Lead SponsorOTHER
Health for a Prosperous Nation
CollaboratorOTHER
Rasello
CollaboratorINDUSTRY
Management and Development for Health
CollaboratorUNKNOWN
Ministry of Health, Tanzania
CollaboratorOTHER_GOV
National Institute of Mental Health (NIMH)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Masking description

Laboratory staff analyzing viral load samples will be blind to intervention/control attribution.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. PLHIV on ART; 2. Age 18 years or older; 3. Phone ownership OR consistent phone access; 4. Not already enrolled in/currently attending enhanced adherence counseling sessions at the facility 5. Living in Geita Region and intends to receive care at a study facility for the next 12 months; 6. Classified as "high-risk" for loss to follow-up (LTFU) from HIV care, and 7. Provides written informed consent for participation

Design outcomes

Primary

MeasureTime frameDescription
12-Month Viral Suppression12 monthsThe proportion of people living with HIV (PLHIV) and on ART with suppressed HIV viral load ( \<1000 copies/ml) at 12 months after study enrollment.

Secondary

MeasureTime frameDescription
6-Month Viral Suppression (<50 copies/ml)6 monthsThe proportion of people living with HIV (PLHIV) and on ART with suppressed HIV viral load ( \<50 copies/ml) at 6 months after study enrollment.
12-Month Viral Suppression (<50 copies/ml)12 monthsThe proportion of people living with HIV (PLHIV) and on ART with suppressed HIV viral load ( \<50 copies/ml) at 12 months after study enrollment.
6-month retention in care6 monthsThe proportion of people living with HIV (PLHIV) on ART at 6 months after study enrollment (PEPFAR considers those not retained on ART to include those who died, disengaged from care, stopped ART, or had no evidence of care for ≥28 days after a missed visit. Participants not found after exhaustive tracing efforts to rule out silent transfers will be classified as not retained on ART)
12-month retention in care12 monthsThe proportion of people living with HIV (PLHIV) on ART at 12 months after study enrollment (PEPFAR considers those not retained on ART to include those who died, disengaged from care, stopped ART, or had no evidence of care for ≥28 days after a missed visit. Participants not found after exhaustive tracing efforts to rule out silent transfers will be classified as not retained on ART)
12-month durable viral load12 monthsProportion with durable HIV viral suppression 12 months after enrollment: at least 2 viral load measurements taken from up to 6 months prior to study enrollment and up to and including 12 months following study enrollment and all are undetectable (\<1000 copies/ml) will have met criteria for durable viral suppression at 12 months.
12-month Appointment Attendance12 monthsThe proportion of scheduled visits that were completed during the 0-12 month period
6-month Appointment Attendance6 monthsThe proportion of scheduled visits that were completed during the 0-6 month period
12-month Mortality12 monthsThe cumulative incidence of mortality at 12 months after study enrollment
6-month Predictive value positive (PVP) of machine learning algorithm6 monthsPredictive value positive (PVP) of the machine learning algorithm in identifying PLHIV at-risk of disengagement from HIV care within 6 months
12-month Predictive value positive (PVP) of machine learning algorithm12 monthsPredictive value positive (PVP) of the machine learning algorithm in identifying PLHIV at-risk of disengagement from HIV care within 12 months
6-month PVP of routine clinical criteria6 monthsPVP of the routine clinical criteria (i.e. recent missed visit or detectable viral load, \>1000 copies/ml) for identifying PLHIV at-risk of disengagement from HIV care within 6 months
12-month PVP of routine clinical criteria12 monthsPVP of the routine clinical criteria (i.e. recent missed visit or detectable viral load, \>1000 copies/ml) for identifying PLHIV at-risk of disengagement from HIV care within 12 months
6-month Predictive value negative (PVN) of the machine learning algorithm6 monthsPredictive value negative (PVN) of the machine learning algorithm in identifying PLHIV not at-risk of disengagement from HIV care within 6 months
12-month PVN of the machine learning algorithm12 monthsPVN of the machine learning algorithm in identifying PLHIV not at-risk of disengagement from HIV care within 12 months
6-month PVN of routine clinical criteria6 monthsPVN of the routine clinical criteria for identifying PLHIV not at-risk of disengagement from HIV care within 6 months
12-month PVN of routine clinical criteria12 monthsPVN of the routine clinical criteria for identifying PLHIV not at-risk of disengagement from HIV care within 12 months
Enhanced Adherence Counseling Session Attendance6 monthsProportion of enhanced adherence counseling sessions completed among sessions scheduled
6-Month Viral Suppression (<1000 copies/ml)6 monthsThe proportion of people living with HIV (PLHIV) and on ART with suppressed HIV viral load ( \<1000 copies/ml) at 6 months after study enrollment.
Viral Suppression with enhanced adherence counseling completion6 monthsProportion with HIV viral suppression after completion of enhanced adherence counseling sessions

Countries

Tanzania

Contacts

PRINCIPAL_INVESTIGATORJingshen Wang, PhD

University of California, Berkeley

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 15, 2026